Danske Bank A S Buys 2,800 Shares of IQVIA Holdings Inc. $IQV

Danske Bank A S grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,366 shares of the medical research company’s stock after buying an additional 2,800 shares during the period. Danske Bank A S’s holdings in IQVIA were worth $20,531,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Korea Investment CORP bought a new stake in shares of IQVIA in the 2nd quarter valued at $13,918,000. National Pension Service raised its stake in IQVIA by 6.6% during the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after buying an additional 23,411 shares during the last quarter. Congress Asset Management Co. bought a new position in IQVIA during the third quarter worth $24,560,000. Deutsche Bank AG acquired a new position in IQVIA in the second quarter valued at $143,074,000. Finally, BlackRock Inc. acquired a new position in IQVIA in the second quarter valued at $2,811,292,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on IQV shares. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $295.00 to $325.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Evercore lifted their price objective on IQVIA from $275.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. UBS Group began coverage on IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price objective on the stock. Jefferies Financial Group upped their target price on IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, Deutsche Bank decreased their target price on IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $294.21.

View Our Latest Analysis on IQVIA

Insider Transactions at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 4,446 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the transaction, the insider owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.70% of the company’s stock.

IQVIA Trading Up 0.0%

NYSE:IQV opened at $265.14 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $43.70 billion, a price-to-earnings ratio of 32.22, a PEG ratio of 2.41 and a beta of 1.16. The firm has a fifty day simple moving average of $267.51 and a two-hundred day simple moving average of $212.00.

IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The business’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 earnings per share. Analysts expect that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Further Reading

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.